Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GtreeBNT Aims To Validate Business Model Via Licensing Deals

Executive Summary

2017 may be a milestone year for GtreeBNT as it progresses its late clinical stage pipeline in the US for various high-need indications including glioblastoma, the South Korean bioventure’s CEO assuring investors that he expects to see “good results” in the near future as it seeks licensing deals for its assets.

Advertisement

Related Content

INTERVIEW: GtreeBNT Looks To Novelty, Deals To Become Dry Eye Player
Shire To Launch Potential Dry Eye Blockbuster After FDA Backs Xiidra

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register